RE:RE:RE:RE:RE:RE:RE:RE:What is going on ?Yes Bluemoons20 it is encouraging to see some interest in buying Replicel shares even if it is at $.055.
I am beginning to think that possibly the Privatization idea is not getting a lot of traction from the bigger shareholders. I am quite surprised that the big pharmaceutical companies are not sniffing around Replicel. With the proper injection of research capital RCH-01 is a viable hair treatment. I think all investors including Jamie and Andrew would take $.30-$.40 per share at this point and move on.
With 65,000,000 share outstanding this is what it would look like:
65,000,000 x $.30 = $19,500,000
65,000,000 x $.40 = $26,000,000
I think the value of Replicel at this point is totally dependent on the Shiseido Trials. Were the results enough for Shiseido to take the procedure to market ? If Shiseido proceeds with marketing this hair treatment, Replicel's value will skyrocket.
It is hard to access the value of the Dermal Injector. At this point we don't know how the dermal industry will value this type of device.